Science
Pioneering a novel approach to immunotherapy
The innate immune system
In the 1960s, early work into xenotransplantation identified a powerful immune response driven by the presence of alpha-gal glycans. Humans, who are naturally exposed to these antigens in the gut, build up an extensive repertoire of anti-glycan antibodies throughout their lives.
We have developed Alphamer® immunotherapy technology to exploit this fundamental biology, precisely directing a potent immune response towards disease targets, including difficult-to-treat infections.
The Alphamer® Platform
Utilising a novel, modular design built around our proprietary linker technology, Alphamers® bind disease targets whilst simultaneously presenting selected anti-glycan antibodies to the immune system, allowing for rapid and effective immune-driven clearance of target cells.
With the Alphamer® approach, we are able to develop precision immunotherapeutics that can be applied to all patients, including those that are vulnerable or immune-compromised.
